Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ketamine shows promise for teen depression in small trial

NCT ID NCT05045378

Symptom relief Sponsor: Taipei Veterans General Hospital, Taiwan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether low-dose ketamine infusions could quickly reduce depression in teenagers aged 13 to 19 whose depression had not improved with at least two other antidepressants. The trial was small, with only 12 participants, and compared ketamine to a placebo (midazolam). The goal was to see if ketamine could provide rapid relief for treatment-resistant depression in adolescents.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ketamine
What this could lead to
If it works, this could point toward a fast-acting treatment option for teenagers with depression that hasn't responded to other medications.
What could go wrong
This is a very small, early-phase study with only 12 participants, so results may not apply to everyone. Ketamine can cause side effects like dizziness or dissociation, and its long-term effects in teens are not well known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

12 people

The number who actually took part.

Started

Mar 2022

Finished

Nov 2024

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

13 to 29 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Major depressive episode including unipolar and bipolar depression, according to DSM- 5 criteria and MINI-adolescent version (Mini-International Neuropsychiatric Interview; MINI) diagnostic interview. 2. Age 13 to 19 years old. 3. Body weigh ≧ 30 kg. 4. Treatment-resistant depression, which is defined as poor or unsatisfactory response to at least two different antidepressants administered at an adequate dosage and for an adequate treatment duration 5. Still prominent depressive symptoms with at least 4-week treatment of medication treatment or psychotherapy 6. Voluntary patients and their parents or guardians with signed informed consent proved by institutional review board (IRB) Exclusion Criteria: 1. Major medical conditions (e.g., head injury, epilepsy, severe renal diseases and cancer). 2. Other axis I psychiatric disorders such as schizophrenia, delusional disorder, organic brain syndrome, and dementia. 3. Pregnancy. 4. Substance abuse in previous 6 months such as cocaine, marijuana, opium, ketamine, PCP (phencyclidine)。 5. Current use of NMDA receptor antagonist (Amantadine, Rimantadine, Lamotrigine, Memantine, Dextromethorphan) 6. Alcohol abuse / dependence within 6 months. 7. Attempt suicide in hospital. 8. Allergy to ketamine 9. Abnormal liver function in recent 3 months。 10. Abnormal ECG (i.e.:arrhythmia)。 11. Fever or infection in recent 5 days。

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Major depressive disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Depressive Disorder, Treatment-Resistant major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Major depressive disorder Treatment-resistant depression

Contacts and locations

Locations

  • Taipei Veterans General Hospital, Taiwan

    Taipei, 112, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.